首页> 美国卫生研究院文献>Journal of Biomedical Science >Investigating the potential of Shikonin as a novel hypertrophic scar treatment
【2h】

Investigating the potential of Shikonin as a novel hypertrophic scar treatment

机译:研究紫草素作为新型肥厚性瘢痕治疗的潜力

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundHypertrophic scarring is a highly prevalent condition clinically and results from a decreased number of apoptotic fibroblasts and over-abundant production of collagen during scar formation following wound healing. Our previous studies indicated that Shikonin, an active component extracted from Radix Arnebiae, induces apoptosis and reduces collagen production in hypertrophic scar-derived fibroblasts. In the study reported here, we further evaluate the potential use of Shikonin as a novel scar remediation therapy by examining the effects of Shikonin on both keratinocytes and fibroblasts using Transwell® co-culture techniques. The underlying mechanisms were also revealed. In addition, effects of Shikonin on the expression of cytokines in Transwell co-culture “conditioned” medium were investigated.
机译:背景肥厚性瘢痕在临床上是一种高度普遍的疾病,其原因是伤口愈合后瘢痕形成过程中凋亡的成纤维细胞数量减少和胶原蛋白的过量生产。我们以前的研究表明,紫草,从紫草中提取的活性成分,可诱导细胞增生并减少增生性瘢痕衍生成纤维细胞的胶原蛋白生成。在本文报道的研究中,我们通过使用Transwell®共培养技术检查了Shikonin对角质形成细胞和成纤维细胞的作用,进一步评估了Shikonin作为一种新型疤痕修复疗法的潜在用途。还揭示了潜在的机制。此外,研究了紫草素对Transwell共培养“条件”培养基中细胞因子表达的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号